Logo of Imugene (ASX:IMU)Latest Imugene (ASX:IMU) News

Page 1
Page 1 of 4

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Imugene’s azer-cel responses strengthen as cash runway shrinks to 0.70 quarters

Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
30 Oct 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Imugene Logs Third Response in BTKi-Resistant Lymphoma Cohort Amid CEO Departure

Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.
Ada Torres
27 July 2026

Market Wrap - Week 28 (6 July -> 10 July) 2026

Mining news drove the week, with drilling hits, funding wins and takeover bids pushing several small and mid-cap names sharply higher or lower. The biggest swings came from tin, platinum group metals and copper, while gold M&A in WA stayed at the centre of trading.
Logan Eniac
11 July 2026

Healthcare Wrap - Week 28 (6 July -> 10 July) 2026

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.
Logan Eniac
11 July 2026

Imugene Raises $11.1 Million to Fuel Azer-cel’s Clinical Momentum

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.
Ada Torres
7 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Imugene’s Azer-cel Hits Complete Response in BTKi-Resistant Mantle Cell Lymphoma Patient

Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.
Ada Torres
1 July 2026

Imugene’s Azer-cel Shows Complete Response in BTKi-Resistant Follicular Lymphoma Patient

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.
Ada Torres
30 June 2026

Healthcare Wrap - Week 24 (8 June -> 12 June) 2026

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.
Logan Eniac
13 June 2026

Imugene’s Azer-cel Secures FDA Fast Track for Two Blood Cancers

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.
Ada Torres
9 June 2026